Sana Biotechnology, Inc.(SANA) Stock Research - Grey Stern Research

Sana Biotechnology, Inc. (SANA) Stock Analysis

$3.86 (6.34%)

SANA Financial Performance


Use the table below to view Sana Biotechnology, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $3.86 -
52 Week Low $1.52 -
52 Week High $12.00 -
Market Cap $861.8 Million 7/18
Gross Margin 0% 10/18
Profit Margin 0% 3/18
EBITDA margin -100% 4/18
Q3 - 2024 Revenue $0 11/18
Q3 - 2024 Earnings -$59.9 Million 15/18
Q3 - 2024 Free Cash Flow -$55.9 Million 16/18
Trailing 4 Quarters Revenue $0 13/18
Trailing 4 Quarters Earnings -$305.8 Million 16/18
Quarterly Earnings Growth -6190% 18/18
Annual Earnings Growth 10% 11/18
Quarterly Revenue Growth 0% 6/18
Annual Revenue Growth 0% 6/18
Cash On Hand $127.0 Million 7/18
Short Term Debt $10.6 Million 5/18
Long Term Debt $85.5 Million 3/18

Sana Biotechnology, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Sana Biotechnology, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/18
PS -1.00 13/18
PB 2.95 6/18
PC 6.79 8/18
Liabilities to Equity 0.91 5/18
ROA -0.55 15/18
ROE -1.05 16/18
Current Ratio 2.10 13/18
Quick Ratio 0.75 16/18
Long Term Debt to Equity 0.29 5/18
Debt to Equity 0.33 5/18
Burn Rate 1.92 6/18
Cash to Cap 0.15 11/18
CCR 0.93 5/18
EV to EBITDA -1.00 4/18
EV to Revenue -1.00 13/18

Company Details

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

CEO: Dr. Steven D. Harr

Website: https://www.sana.com

Address: 188 East Blaine Street Seattle, WA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Sana Biotechnology, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Sana Biotechnology, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Blueprint Medicines Corporation BPMC $6.7 Billion
Apellis Pharmaceuticals, Inc. APLS $3.6 Billion
aTyr Pharma, Inc. LIFE $131.1 Million
HOOKIPA Pharma Inc. HOOK $18.6 Million
X4 Pharmaceuticals, Inc. XFOR $78.6 Million
Revolution Medicines, Inc. RVMD $7.3 Billion
Galera Therapeutics, Inc. GRTX $2.5 Million
Zentalis Pharmaceuticals, Inc. ZNTL $203.1 Million
Generation Bio Co. GBIO $59.3 Million
Nkarta, Inc. NKTX $158.1 Million
Olema Pharmaceuticals, Inc. OLMA $409.8 Million
Kymera Therapeutics, Inc. KYMR $2.8 Billion
Lyell Immunopharma, Inc. LYEL $174.5 Million
Monte Rosa Therapeutics, Inc. GLUE $383.4 Million
Terns Pharmaceuticals, Inc. TERN $393.3 Million
Day One Biopharmaceuticals, Inc. DAWN $1.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
SANA Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 0 -$59.9 Million
Q2 2024 $ 0 -$50.3 Million
Q1 2024 $ 0 -$107.5 Million
Q4 2023 $ 0 -$88.1 Million
Q3 2023 $ 0 $984,000
Q2 2023 $ 0 -$114.0 Million
Q1 2023 $ 0 -$80.2 Million
Q4 2022 $ 0 -$78.4 Million

View All

SANA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $127.0 Million $559.4 Million $96.1 Million $292.5 Million
Q2 2024 $138.8 Million $618.7 Million $98.6 Million $339.6 Million
Q1 2024 $177.1 Million $681.4 Million $106.1 Million $375.1 Million
Q4 2023 $137.3 Million $565.3 Million $104.1 Million $287.5 Million
Q3 2023 $168.4 Million $631.4 Million $96.9 Million $365.9 Million
Q2 2023 $173.8 Million $707.1 Million $113.1 Million $355.0 Million
Q1 2023 $160.5 Million $746.9 Million $114.5 Million $428.3 Million
Q4 2022 $176.8 Million $822.7 Million $108.3 Million $499.3 Million

View All

SANA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$55.9 Million -$4.1 Million -$8.0 Million
Q2 2024 -$71.6 Million -$13.1 Million -$42.1 Million
Q1 2024 -$81.5 Million -$15.8 Million $43.5 Million
Q4 2023 -$66.0 Million -$14.0 Million -$34.9 Million
Q3 2023 $0 $0 $0
Q2 2023 -$60.4 Million -$1.6 Million $13.3 Million
Q1 2023 -$81.4 Million -$2.2 Million -$16.3 Million
Q4 2022 -$80.7 Million -$4.6 Million $13.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions